GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PDL BioPharma Inc (NAS:PDLI) » Definitions » Tax Expense

PDL BioPharma (PDL BioPharma) Tax Expense : $-20.12 Mil (TTM As of Jun. 2020)


View and export this data going back to 1992. Start your Free Trial

What is PDL BioPharma Tax Expense?

PDL BioPharma's tax expense for the months ended in Jun. 2020 was $-1.08 Mil. Its tax expense for the trailing twelve months (TTM) ended in Jun. 2020 was $-20.12 Mil.


PDL BioPharma Tax Expense Historical Data

The historical data trend for PDL BioPharma's Tax Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PDL BioPharma Tax Expense Chart

PDL BioPharma Annual Data
Trend Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19
Tax Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 197.34 45.71 73.83 12.94 -3.05

PDL BioPharma Quarterly Data
Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20
Tax Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.58 -1.94 -2.63 -14.47 -1.08

PDL BioPharma Tax Expense Calculation

Tax paid by the company. It is computed in by multiplying the income before tax number, as reported to shareholders, by the appropriate tax rate. In reality, the computation is typically considerably more complex due to things such as expenses considered not deductible by taxing authorities ("add backs"), the range of tax rates applicable to various levels of income, different tax rates in different jurisdictions, multiple layers of tax on income, and other issues.

Tax Expense for the trailing twelve months (TTM) ended in Jun. 2020 adds up the quarterly data reported by the company within the most recent 12 months, which was $-20.12 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


PDL BioPharma  (NAS:PDLI) Tax Expense Explanation

In the long run, income before tax and taxable income will likely be more similar than they are in any given period. If the one is less in earlier years, then it will be greater in later years. Deferred taxes will reverse themselves in the long run and in total will zero out, unless there is something like a change in tax rates in the intervening period. A deferred tax payable results from a tax break in the early years and will reverse itself in later years; a deferred tax receivable results from more taxes being paid in early years than the tax expense reported to shareholders and will again reverse itself in later years. The deferred tax amount is computed by estimating the amount and the timing of the reversal and multiplying that by the appropriate tax rates.


PDL BioPharma Tax Expense Related Terms

Thank you for viewing the detailed overview of PDL BioPharma's Tax Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


PDL BioPharma (PDL BioPharma) Business Description

Traded in Other Exchanges
N/A
Address
932 Southwood Boulevard, Incline Villiage, NV, USA, 89451
PDL BioPharma Inc acquires and manages a portfolio of companies, products, royalty agreements and debt facilities in the biotech, pharmaceutical and medical device industries. The operating segments of the company are Medical Devices, Strategic Positions, Pharmaceutical and Income Generating Assets, of which key revenue is derived from the Pharmaceutical segment. The Pharmaceutical segment consists of revenue derived from branded prescription medicine products sold under the name Tekturna and Tekturna HCT in the U.S, and Rasilez and Rasilez HCT in the rest of the world (collectively, the Noden Products). Geographically, the company operates in Europe, North America, Asia and Other countries, of which prime revenue is generated from Asia and North America.
Executives
David W Gryska director 749 N MARY AVE, SUNNYVALE CA 94085
John Peter Mclaughlin director C/O PDL BIOPHARMA, INC., 932 SOUTHWOOD BOULEVARD, INCLINE VILLAGE NV 89451
Dominique Monnet officer: President and CEO C/O ALEXION PHARMACEUTICALS, INC., 352 KNOTTER DRIVE, CHESHIRE CT 06410
Christopher Lewis Stone officer: VP, Gen. Counsel & Secretary 932 SOUTHWOOD BLVD. INCLINE VILLAGE NV 89451
Alan Lee Bazaar director 9 BEDFORD ROAD, KATONAH NY 10536
Natasha Hernday director 932 SOUTHWOOD BLVD, INCLINE VILLAGE NV 89451
Edward Imbrogno officer: VP Finance, CAO and Acting CFO 932 SOUTHWOOD BLVD. INCLINE VILLAGE NV 89451
Jill M. Jene officer: VP, Business Development 932 SOUTHWOOD BLVD., INCLINE VILLAGE NV 89451
Harold E Selick director
Samuel R Saks director 3180 PORTER DRIVE, PALO ALTO CA 94304
Paul W Sandman director C/O PDL BIOPHARMA, INC., 932 SOUTHWOOD BLVD, INCLINE VILLAGE NV 89451
Shlomo Yanai director ONE MEADOWLANDS PLAZA, EAST RUTHERFORD NJ 07073
Peter S Garcia officer: Vice President, CFO ALX ONCOLOGY HOLDINGS INC., 866 MALCOLM ROAD, SUITE 100, BURLINGAME CA 94010
Jody S Lindell director 2536 FILLMORE ST., SAN FRANCISCO CA 94115
Paul R Edick director C/O NEWLINK GENETICS CORP., 2503 SOUTH LOOP DR., SUITE 5100, AMES IA 50010